Researchers are currently experimenting in laboratories on the bioavailability of oral-buccal administration of peptide compared to the subcutaneous route, and results so far show that 1mg of peptide administered sublingually daily is equivalent to 5mg administered subcutaneously weekly. The research aims to suggest alternative methods for alleviating redness, pain, swelling, and total body chills, as well as muscular pain, triggered by subcutaneous administration in approximately 20% of the population.